These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37385277)

  • 21. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
    Phizackerley D
    BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
    [No Abstract]   [Full Text] [Related]  

  • 22. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
    Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
    Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Add-on value of tirzepatide versus semaglutide.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 25. Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    Weghuber D; Kelly AS; Arslanian S
    N Engl J Med; 2023 Mar; 388(12):1146. PubMed ID: 36947476
    [No Abstract]   [Full Text] [Related]  

  • 26. Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
    Cardiol Rev; 2023 Jan-Feb 01; 31(1):57. PubMed ID: 36469361
    [No Abstract]   [Full Text] [Related]  

  • 27. Semaglutide in routine clinical practice: interesting news from real-world evidence.
    Formoso G; Baroni MG
    J Endocrinol Invest; 2022 Aug; 45(8):1599-1600. PubMed ID: 35524036
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

  • 30. Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.
    Liuzzo G; Patrono C
    Eur Heart J; 2024 Feb; 45(8):570-571. PubMed ID: 38103177
    [No Abstract]   [Full Text] [Related]  

  • 31. Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
    Admani B; Fahim M; Ahmed H
    J Pak Med Assoc; 2024 Jun; 74(6):1204. PubMed ID: 38949006
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
    Villela R; Correa R
    J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
    [No Abstract]   [Full Text] [Related]  

  • 34. A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.
    Carney EF
    Nat Rev Nephrol; 2024 Aug; 20(8):493. PubMed ID: 38956439
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    Hansen MK; Olesen KKW; Gyldenkerne C; Thrane PG; Stødkilde-Jørgensen N; Mortensen MB; Maeng M
    J Am Coll Cardiol; 2024 Mar; 83(9):956-958. PubMed ID: 38418010
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.